RARE vs TMDX · rev $350.0M vs P/E 17, rev $363.9M
Ultragenyx (RARE) versus TransMedics Group Inc (TMDX) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
TransMedics Group Inc (TMDX) is a medical devices company listed on NASDAQ.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported TMDX revenue for 2026-06-30 was $363.9M. Net income was $22.0M. TMDX currently screens at market cap $2.53B and trailing P/E 16.8.
RARE currently screens at market cap $2.79B. TMDX currently screens at market cap $2.53B and trailing P/E 16.8.
Not investment advice. Open the RARE and TMDX stock pages for the full models.
Not investment advice.